Dr. Henry has extensive experience in intellectual property law in the areas of biotechnology, pharmaceuticals, and medical diagnosis and treatment. Her patent practice encompasses patentability opinions, patent drafting, domestic and foreign patent prosecution, development and management of patent portfolios, patent landscape surveys, patent mapping and strategic planning, due diligence analysis, and general client counseling. Representative clients include major and mid-sized biopharmaceutical companies, a small biotechnology company, and universities. Dr. Henry is admitted to practice before the U.S. Patent and Trademark Office.
Dr. Henry received her B.A. in botany from the University of North Carolina, and her M.S. and Ph.D. in botany from Duke University. As an undergraduate, she received the Francis J. LeClair Award for outstanding student in botany and was elected a member of Phi Beta Kappa. At Duke, Dr. Henry was inducted into Sigma Xi, the scientific research society. As an R.J. Reynolds Postdoctoral Fellow in the Department of Soil Science at North Carolina State University, Dr. Henry’s research focused on plant nitrogen and carbohydrate metabolism. As a faculty member in the Department of Forestry at North Carolina State University, her research and teaching activities concentrated on genetic and environmental effects on plant physiological and biochemical processes.
- Successfully prosecuted patents in the United States for recombinant protein-based medical therapies and in foreign countries for second-medical use of these proteins, including therapies for cardiovascular diseases, HIV, cancer, and autoimmune disorders, on behalf of a major biopharmaceutical company.
- Development and management of a patent portfolio surrounding second-generation pharmaceutical protein composition, including patent mapping and strategic planning, on behalf of a major biopharmaceutical company.
- Coordinated a patent mapping project and the strategic planning for stem cell compositions and therapies, on behalf of a mid-sized biopharmaceutical company.
- Development and management of a patent portfolio surrounding an anti-cancer antibody currently in clinical trials, on behalf of a major biopharmaceutical company.
- Management of a patent portfolio directed to second-generation protein expression platform technology for a small biotechnology company.
- Development and management of a patent portfolio surrounding optimized therapeutics, on behalf of a small biotechnology company.
- North Carolina Bar Association - Intellectual Property Law Section